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Abstract
The construction and application of biological network models is an approach
that offers a holistic way to understand biological processes involved in
disease. Chronic obstructive pulmonary disease (COPD) is a progressive
inflammatory disease of the airways for which therapeutic options currently are
limited after diagnosis, even in its earliest stage. COPD network models are
important tools to better understand the biological components and processes
underlying initial disease development. With the increasing amounts of
literature that are now available, crowdsourcing approaches offer new forms of
collaboration for researchers to review biological findings, which can be applied
to the construction and verification of complex biological networks. We report
the construction of 50 biological network models relevant to lung biology and
early COPD using an integrative systems biology and collaborative
crowd-verification approach. By combining traditional literature curation with a
data-driven approach that predicts molecular activities from transcriptomics
data, we constructed an initial COPD network model set based on a previously
published non-diseased lung-relevant model set. The crowd was given the
opportunity to enhance and refine the networks on a website (
) and to add mechanistic detail, as well ashttps://bionet.sbvimprover.com/
critically review existing evidence and evidence added by other users, so as to
enhance the accuracy of the biological representation of the processes
captured in the networks. Finally, scientists and experts in the field discussed
and refined the networks during an in-person jamboree meeting. Here, we
describe examples of the changes made to three of these networks: Neutrophil
, , and . We describe anSignaling Macrophage Signaling Th1-Th2 Signaling
innovative approach to biological network construction that combines literature
and data mining and a crowdsourcing approach to generate a comprehensive
set of COPD-relevant models that can be used to help understand the
mechanisms related to lung pathobiology. Registered users of the website can
freely browse and download the networks.
 Julia Hoeng ( )Corresponding author: Julia.Hoeng@pmi.com
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Introduction
Molecular networks, such as the KEGG (Kyoto Encyclopedia of 
Genes and Genomes) pathways1,2, aid in understanding the complex 
interplay of signaling pathways in disease. Biological network mod-
els (hereafter referred to as networks) depict the inter-relationships 
between multiple signaling pathways and how their perturbations 
may dysregulate biological processes, eventually leading to the 
disease.
In previously published reports, we described the construction of a 
set of 90 networks that captured a large range of biological proc-
esses relevant to non-diseased lung tissue3–7. The generation of this 
set of networks relied on both manual curation of published litera-
ture and a data-driven reverse causal reasoning (RCR) methodol-
ogy8 to augment the causal biological framework underlying the 
network architecture (Figure 1). We used the Biological Expres-
sion Language (BEL) to represent precise biological relationships 
in a computable and standardized format8. We have built upon this 
approach and describe here a unique, three-phase systems biology 
and crowdsourcing approach to construct a comprehensive set of 
50 molecular networks that describe the biological processes rel-
evant to chronic obstructive pulmonary disease (COPD) and lung 
biology (Figure 2). COPD is the fourth leading cause of death 
worldwide and its incidence is increasing among chronic diseases 
in the USA9,10. COPD is a chronic, progressive inflammatory dis-
ease induced by cigarette smoking, inhalation of pollutants, dust, 
chemicals, or other foreign matter, which ultimately manifests as 
tissue destruction in the alveolar compartments and airflow limita-
tion, leading to reduced oxygen exchange11–15. COPD affects a wide 
spectrum of biological processes in lung tissue, such as oxidative 
stress, inflammation, apoptosis, proliferation, and senescence16,17. 
Understanding the mechanisms involved in these processes is 
important in understanding the onset of the disease and in iden-
tifying drug targets to develop effective COPD treatments18,19. As 
recently reported by the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD), current pharmacologic therapies cannot 
cure the disease but only reduce the symptoms, and the frequency 
and severity of exacerbations, i.e., slow down the rate of disease 
progression11; thus it appears most efficient to target the COPD-
specific pathomechanisms at the earliest distinguishable state, when 
the extent of irreversible damage is still small, and their molecu-
lar processes are not yet convoluted with secondary processes and 
comorbidities, e.g., bacterial and viral infections, as they occur dur-
ing the exacerbations typical for later stages of COPD. Since smok-
ing cessation/replacement appears to be the most efficient therapy 
in smoking-related COPD11, the models of early onset COPD can 
also be expected to be valuable tools for the development and test-
ing of reduced risk products that may prevent COPD progression in 
a comparable manner as cessation does.
The networks reported here were created first from a literature scaf-
fold and expanded via data enhancement using RCR (Phase 1), then 
they were made available online to the entire scientific commu-
nity for critical review during the Network Verification Challenge 
(NVC) “Open Phase” (Phase 2) under the umbrella of the systems 
biology verification (sbv) IMPROVER project20 (Figure 1). Finally, 
a prioritized subset of 15 of these networks was discussed during an 
in-person jamboree meeting where the crowd-submitted revisions 
were reviewed and decisions to improve the networks were final-
ized (Phase 3). The final versions of the networks are available at 
https://bionet.sbvimprover.com for the public to view, and for reg-
istered users in the NVC to continue to discuss.
A variety of COPD networks have been created by various research 
groups, including networks focused on muscle to study skeletal 
muscle abnormalities21, networks to compare COPD and asthma22, 
and a knowledge management framework to integrate COPD clini-
cal and experimental data23. To our knowledge, this is the first set 
of crowd-verified networks available to the broader scientific com-
munity as a unified collection on a freely accessible web-based 
platform. Ultimately, this interface will allow for continuous input 
and improvement in the networks, leading to better understanding, 
diagnosis, and treatment of COPD.
Methods
Results
Data File
2 Datasets
http://dx.doi.org/10.6084/m9.figshare.1284583
Phase 1: COPD enhancements using data and literature
Ninety non-diseased lung networks published previously in the 
areas of cell proliferation, cell stress, inflammation, DNA damage, 
      Amendments from Version 1
The changes made in the manuscript are as follows:
- We further explained the sentence on page starting “Networks 
that were not enhanced with COPD-specific mechanisms from 
the literature or RCR included …” by adding : “Although there 
may be papers that report on the correlation between COPD and 
these processes, network model building requires mechanistic 
information that will provide causal links within the model”.
- We have added several references to demonstrate how the 
biological signal is interpreted in a meaningful manner using the 
causal network models (p. 17).
- When describing the improvements on the Th1-Th2 signaling 
network, we have used “more comprehensive” instead of 
“comprehensive” (p. 11).
- We have specified in the text (p. 15) that the 886 pieces of 
evidence added by the crowd is supported by 479 unique PMIDs.
- We have added a clearer legend for Figure 4 explaining what 
the different shaped nodes represent in the networks.
- We have modified Figure 1 and the figure legend explaining the 
difference between BEL and OpenBEL (p. 4).
- Figure 2 was slightly modified to better reflect the structure of 
the articles in which the networks were originally described. More 
specifically, the icon for mucus hypersecretion was moved to 
inflammation and response to DNA damage to cell fate.
- We have indicated appropriate references in the discussion 
for readers, who wish to find more background information 
about the network models and see how they compare with other 
approaches to interpret data (p. 16). 
See referee reports
REVISED
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Figure 1. Network construction using a systems biology and crowdsourcing approach. Networks were constructed using published 
literature and data sets, and opened to the public for comment and editing in the Network Verification Challenge. The three phases of COPD 
network construction are shown. (A and B) Phase 1: COPD augmentation using literature and data. (C and D) Phase 2: Online verification by 
the public during an “open phase”, and Phase 3: Face-to-face jamboree meeting where scientists and subject matter experts gathered to 
discuss the networks and make final decisions for the next versions. *BEL was a proprietary language developed by Selventa. In the interest 
of the growing community of researchers using BEL, an openBEL language derived from BEL has been developed and released as open 
source. One of the main differences between the two is that in the openBEL, the namespace (i.e. databases in which the biological entity is 
defined) is clearly stated, allowing for a better standardization of used ontologies and databases.
cell death, tissue repair, and angiogenesis were used as the initial 
scaffolds for COPD enhancement during Phase 13–7. Biological 
pathways implicated in COPD disease pathophysiology, includ-
ing B-cell and T-cell activation, airway remodeling, extracellular 
matrix (ECM) degradation, efferocytosis, mucus hypersecretion, 
and emphysema were all captured within the modified network 
models. In total, 200 new nodes and 487 new edges were added: 
415 of the edges were added to incorporate COPD mechanisms 
implicated in the literature, and 72 edges were added to incorporate 
100 mechanisms predicted from COPD data by RCR to be relevant 
to COPD (Figure 3). Because the models were built to represent 
COPD in humans, human evidence was preferred and made up the 
majority of the networks (74%).
During Phase 1, the networks with the most significant number of 
COPD enhancements in terms of percentage of the network with 
new nodes were the Mucus Hypersecretion (44%), Th2 Signaling 
(37%), Macrophage Activation (28%), Fibrosis (25%), Autophagy 
(11%), and Apoptosis (5%) networks. Networks that were not 
enhanced with COPD-specific mechanisms from the literature or 
RCR included the DNA Damage and Notch Signaling networks. 
Although both these networks relevant to the development of 
COPD, they were not augmented beyond the original, non-diseased 
network scaffolds, because no studies on the differences in signaling 
between non-diseased and diseased states were available. Although 
there may be papers that report on the correlation between COPD 
and these processes, network model building requires mechanistic 
information that will provide causal links within the model.
Phase 2: Networks enhanced with lung- and COPD-relevant 
mechanisms by the crowd during the open phase
Prior to deploying the COPD-enhanced biological networks on the 
NVC website for verification by the scientific community, the set 
of 90 networks was agglomerated by the model-building expert 
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Figure 2. Fifty networks available during the network verification challenge and their associated biological processes.
team to yield a more concise set of 50 networks that combined 
and standardized related/complementary cellular pathways (See 
Methods for details). For example, a new “Th1 Signaling” net-
work model was created by merging three of the original networks 
that were relevant to the functional biology present in T-helper 1 
cell populations: Th1 Differentiation, Th1 Response, and T-cell 
Recruitment and Activation. For a list of the original models that 
correspond to the agglomerated models and a description of the 
new models, see Dataset.
During Phase 2, a global community of scientists participated in 
the NVC by contributing their expertise to one or several of the 
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network models. Scientists could contribute by verifying existing 
evidence for network edges using a system that allowed users to 
vote on evidence to indicate agreement or disagreement with its 
appropriateness within the network structure and boundary con-
ditions. Participants were also encouraged to add new mechanis-
tic biology in the form of network edges. In total, the 50 network 
models received 2456 evidence votes, 1795 of which supported 
the confirmation of evidence and 661 that favored the rejection of 
evidence (see Dataset). The Neutrophil Signaling network model 
received the largest share of voting activity, with 241 total votes 
or approximately 10% of all votes cast. Other network models that 
received large shares of the votes included the Macrophage Signal-
ing (180 votes) and Th1 and Th2 Signaling network models (105 
votes) (see Dataset). In addition to verifying existing literature evi-
dence supporting edges in the network models, NVC participants 
could add novel biological information in the form of new literature 
evidence (for an existing edge) or contribute new network edges to 
incorporate new biological components into the network structure. 
In this way, the community of participants collectively contributed 
a significant amount of new information into the networks; among 
the 50 network models, a total of 885 new pieces of evidence, 351 
new nodes, and 451 new edges were added (Figure 3).
Phase 3: Jamboree discussion and final decisions for next version 
networks
Following Phase 2, a jamboree (Phase 3) was organized for a 
group of invited participants to discuss the network enhancements 
submitted by the crowd. To represent the crowd community, the 
top 20 active performers who created the most pieces of evidence 
and submitted at least 20 votes during the NVC were invited to an 
in-person jamboree to discuss network refinements as a group. 
Additional subject matter experts in the network biology, COPD, 
lung biology, and biological processes represented by the networks 
were invited to participate in the discussions and contribute their 
expert feedback independent from the network-building experts. 
Among the 50 network models evaluated during the online NVC, 
15 were prioritized and selected for discussion during Phase 3 
based on the level of crowd-sourced activity and their importance 
in COPD onset as considered by the network-building experts (see 
Dataset). The goal of Phase 3 was to provide an additional layer of 
“verification” for the online enhancements and to provide holistic 
comments on the network models at the molecular/biological entity 
level. In doing so, the three network models that had received the 
largest amounts of crowd activity (Neutrophil Signaling, Macro-
phage Signaling, and Th1 Signaling) also underwent significant 
additional enhancements to improve granularity with respect to 
COPD onset and pathogenesis. In total, 167 nodes and 296 edges 
were added among all the network models reviewed during the 
jamboree sessions, and the three inflammatory networks received 
89% of the nodes and 89% of the edges (148 nodes and 263 edges) 
(Figure 3). Many of these changes came from the identification of 
missing mechanistic details of processes that occur in COPD (e.g. 
chemotaxis mechanisms in the Macrophage Signaling network 
model described in the examples in the “Macrophage signaling” 
section below).
In addition to adding mechanistic details of processes that occur 
in COPD, enhancements were incorporated to improve the gran-
ularity and connectivity within the network structures. In sev-
eral instances, the improvements involved the creation of more 
Figure 3. Nodes and edges added in each phase of COPD network construction. Summary of nodes and edges added to all networks 
and to three example networks in each phase. A) Nodes added in each phase. B) Edges added in each phase.
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0 100 200 300 400 500
Count
Nodes
All networks
Macrophage Signaling
Neutrophil Signaling
Th1-Th2 Signaling
Edges
All networks
Macrophage Signaling
Neutrophil Signaling
Th1-Th2 Signaling
200
351
167
45
23
30
116
69
9
30
10
49
487
451
296
61
39
48
160
129
20
34
86
9
Phase
Phase 1
Phase 2
Phase 3
Page 6 of 29
F1000Research 2015, 4:32 Last updated: 14 JUN 2016
detailed linear pathways connecting biological components. In one 
example, in the Apoptosis network model, the original network 
pathway indicated that the X-ray repair complementing defective 
repair in Chinese hamster cells 6 (XRCC6) protein decreased the 
process of apoptosis24. During the Phase 3 discussions, additional 
literature evidence provided a more detailed mechanistic under-
standing of this phenomenon: XRCC6 was reported to decrease the 
activity of the BCL2-associated X protein (BAX) protein, which 
is known to increase mitochondrial permeability and therefore 
promote apoptosis (Figure 4A). The overall effect of the negative 
regulation of BAX by XRCC6 was therefore a decrease in apop-
totic cell death25. By improving the granularity of this pathway in 
the Apoptosis network, a more comprehensive representation was 
achieved for components that are related to critical cellular proc-
esses mediating disease onset.
A similar improvement was incorporated into the Mechanisms of 
Cellular Senescence network model: the original network pathway 
indicated that the chemical acrolein (a common component of ciga-
rette smoke) increased cell senescence26. During Phase 3 discus-
sions, the pathway connecting these two components was expanded 
using additional literature evidence. In several studies, acrolein was 
found to decrease the activity of sirtuin 1 (SIRT1), which is a known 
negative regulator of the forkhead box O3 (FOXO3) transcription 
factor, and FOXO3 activity is known to promote cellular senes-
cence (Figure 4B)26–28. Therefore, the overall observed effect was 
acrolein acting to potentiate cellular senescence in exposed cells, 
which is a well-characterized mechanism of action for this toxic 
chemical. Again, the generation of more comprehensive network 
models of biological processes in close proximity to disease onset 
allowed for a greater mechanistic understanding of how environ-
mental factors can contribute to COPD development.
Exemplary outcomes of the three-phase COPD network 
building process
Th1 and Th2 signaling
As part of the pulmonary inflammatory process network building6, 
five networks (T-cell activation and recruitment, Th1 differentiation, 
Th2 differentiation, Th1 Response, Th2 response) were built to 
describe Th1 and Th2 signaling in the non-disease lung context. 
As described previously, during the preparation phase to NVC, two 
networks were built around the Th1 and Th2 cells.
Phase 1: COPD augmentation of T-helper cell networks
Mechanisms that describe T-cell activation and recruitment induced 
by neutrophils, macrophages, and dendritic cells were added to 
the T-cell networks during Phase 1. These immune cells secrete 
various chemokines that were reported to recruit T-cell populations 
Figure 4. Improvements in the granularity of two representative network pathways. Cyan squares represent abundances, triangles 
activities, purple squares the movement of abundances from one cellular location to another, and diamonds biological processes. During 
Phase 3 of COPD network construction, improvements were made by adding mechanistic details to over-simplistic edges. A) In the Apoptosis 
network model, the original connection (left) simply indicated that XRCC6 decreased the process of apoptosis. The improved pathway 
connection (right) indicates that XRCC6 decreases the activity of BAX, which normally functions to facilitate the transport of calcium ions 
through the mitochondrial pores and thereby increases apoptosis. B) In the Mechanisms of Cellular Senescence network model, the original 
connection (left) simply indicated that acrolein increased the process of cellular senescence. The improved pathway connection (right) 
indicates acrolein mediates its effects on senescence via the activity of SIRT1 and the FOXO3 transcription factor. Triangle denotes activity, 
diamond denotes biological process or pathology, circle denotes abundance, rounded square represents transport, and square denotes 
protein abundance nodes. Solid edges denote causal relationships, dotted edges denote non-causal relationships such as a protein 
connected to its own activity.
p(HGNC: XRCC6) p(HGNC: XRCC6)
p(HGNC: SIRT1)bp(MESHPP:Apoptosis)
bp(MESHPP:Apoptosis)
cat(p(HGNC:BAX))
tport(a(MESHCL:”mitochondrial
permeability transition pore”))
A
a(CHEBI:acrolein) a(CHEBI:acrolein)
B
path(SDIS:”cell
senescence”
path(SDIS:”cell
senescence”
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(i.e. CD8+ cytotoxic T-cells) to injured tissue in an acute inflam-
matory state29. Alveolar macrophages secrete interleukin 15 (IL15), 
which is capable of activating both the interleukin 2 (IL2) and IL15 
receptors on T-cells and acts as a potent inducer of cell migration to 
the lung. Dendritic cells within the lung play an important role in 
this process by secreting chemokine (C-C motif) ligand 3 (CCL3) 
in response to cigarette smoke, which helps recruit CD8+ T-cells 
to the lung29. Chemokine (C-C motif) receptor 5 (CCR5) is the 
receptor for CCL3 and its presence in the lung has been shown to 
correlate with the severity of COPD30. CCL3 is one example of a 
node that was added during the literature-based COPD enhance-
ment process in Phase 1 (Figure 5A). Many of the disease-relevant 
mechanisms identified in the literature curation phase were cor-
roborated by mechanisms predicted from COPD-relevant data sets 
using RCR (see Methods), including T-cell activation mechanisms 
(CD28 molecule (CD28) and T cell receptor beta locus (T\RB), and 
chemokines and cytokines that activate and are secreted by T-cells 
(chemokine (C-C motif) receptor 3 (CCR3), CCR5, IL2, interleukin 
4 (IL4), interleukin 6 (IL6), interleukin 10 (IL10) and interleukin 
13 (IL13)). The prediction of these mechanisms in COPD data sets 
showed that T-cell activation and migration in response to smoke-
exposed lung represents an important process in the innate immune 
response. In total, 30 nodes and 34 edges were added to the Th1 
and Th2 networks during the internal COPD enhancement process.
Figure 5. Enhancement of the T-cell networks during COPD network construction. A) During the literature-based COPD enhancement 
process in Phase 1, the protein CCL3, important for leukocyte migration and activation of T-cells, was added to the T-cell networks. 
B) During the open phase in Phase 2, the negative regulation of EGR2 on T-cell activation is a mechanistic detail that was added by the 
crowd. Overexpression studies demonstrated that EGR2 increased the activity of the E3 ubiquitin ligase CBL-B, which subsequently inhibited 
T-cell activation. C) During the jamboree discussions in Phase 3, the IFNG/IL-4 feedback loop mediating differentiation of Th1 vs. Th2 cellular 
subtypes via the activities of IRF1 and IRF2 was added to the new Th1-2 Signaling network model. D) During the jamboree discussions in 
Phase 3, the T-helper cell-produced chemokine effect on immune cells (e.g. IL-25 activates memory T-cells) was added to the new Th1-2 
Signaling network. Triangle denotes activity, diamond denotes biological process or pathology, and square denotes protein abundance nodes. 
Solid edges denote causal relationships, dotted edges denote non-causal relationships such as a protein connected to its own activity.
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Phases 2 and 3: T-cell network crowd improvements
During the open phase (Phase 2), the Th1 and Th2 networks 
received 105 votes from the scientific community, as well as 10 
new nodes, 9 new edges, and 13 new pieces of evidence. One such 
addition to the Th1 Signaling network was the regulatory influence 
of early growth response 2 (EGR2) on T-cell activation; the submit-
ted evidence demonstrated that overexpression of EGR2 promoted 
increased activity of the E3 ubiquitin ligase CBL-B and subsequent 
inhibition of T-cell activation31 (Figure 5B).
During the Phase 3 jamboree sessions, the group decided to com-
bine the individual Th1 Signaling and Th2 Signaling networks into 
a single, unified network model titled Th1-Th2 Signaling to bet-
ter represent the interplay between the T-helper cell populations 
in vivo. It was also decided to add granularity to transcriptional 
pathways mediating Th1 versus Th2 cellular activation and differ-
entiation; one example was the addition of two transcription fac-
tors, interferon regulatory factors 1 and 2 (IRF1 and IRF2), that are 
known to act downstream of interferon-gamma (IFNG) to suppress 
IL4 expression in Th2 cell populations32. IFNG is secreted by Th1 
cells and this pathway potentiates Th1 responses while suppressing 
Th2 responses in the tissue. The addition of this feedback mecha-
nism during Phase 3 contributed to a more comprehensive network 
describing the interactions between Th1 and Th2 cells (Figure 5C). 
Further network enhancements discussed in the jamboree largely 
emphasized the downstream effects of T-helper cells in potentiating 
inflammatory signaling by activating additional immune cells in a 
disease context. For example, secretion of IL5 activates eosinophils, 
whereas secretion of IL10 and IFNG activates macrophages in the 
diseased tissue33–35. This interplay between immune cell popula-
tions was incorporated into the new Th1-Th2 Signaling network 
model and better captures the signaling interconnectivity present 
during disease development (Figure 5D). In total, 12 new nodes 
and 28 new edges were added to the Th1-Th2 Signaling network 
model during the jamboree discussions, thereby creating a more 
comprehensive biological network of T-helper cell activity and 
their interactions with other immune cells in the context of COPD.
Macrophage signaling
As part of the pulmonary inflammatory process network building6, 
three networks (Macrophage Differentiation, Macrophage Activa-
tion, and Macrophage-mediated Recruitment of Neutrophils) were 
built to describe macrophage biology in the non-disease lung con-
text. During the preparation phase to NVC, these three networks 
were merged to obtain an overall picture of macrophage biology.
Phase 1: COPD augmentation of macrophage networks
Macrophages play roles in many COPD disease processes such as 
clearance of apoptotic neutrophils, tissue destruction, and recruitment 
of other immune cells by their secretion of cytokines36. Macro-
phage signaling mechanisms were added to the network in Phase 1, 
with a focus on components related to efferocytosis (Figure 6A). 
Efferocytosis is a well-conserved mechanism for the phagocytic 
removal of apoptotic cells by innate immune cells, such as mac-
rophages, and the process is critical for the resolution of inflam-
mation via the removal of dying cells and antigenic cellular debris. 
Phagocytically impaired macrophages have been shown to dis-
play decreased expression of peroxisome proliferator-activated 
receptor gamma (PPARy) and efferocytosis-specific bridge mol-
ecules, such as growth arrest-specific 6 (GAS6) and milk fat glob-
ule-EGF factor 8 protein (MFGE8)37. The number of apoptotic cells 
was shown to increase in COPD because of exposure of lung tissue 
to toxic chemicals present in cigarette smoke; for example, and their 
accumulation was exacerbated by the simultaneous smoke-induced 
impairment of the phagocytic ability of alveolar macrophages38. 
Apoptotic cells exhibit surface changes that distinguish them from 
viable cells, and these changes were recognized by efferocytic 
receptors including CD36 molecule (CD36), CD14 molecule 
(CD14), and Stabilin-1/2 (STAB1:STAB2)39. Reduced efferocyto-
sis observed in COPD because of oxidant-driven and Rho-mediated 
inactivation increased the likelihood of aberrant antigen exposure 
from apoptotic cells, thereby perpetuating the chronic inflamma-
tory state that is a hallmark of COPD40–42. In adding efferocytosis 
mechanisms to the macrophage network, we focused on the surface 
receptors and bridge proteins such as CD36 and GAS6. In total, 45 
nodes and 61 new edges were added to the macrophage model dur-
ing the internal COPD enhancement phase.
Phases 2 and 3: Macrophage network crowd improvements
During the open phase (Phase 2), 180 total votes were cast for net-
work evidence, with 23 new nodes and 39 new edges added by the 
crowd. In addition, 72 new pieces of evidence were contributed to 
support pre-existing edges in the network. The surfactant protein 
A1 (SFTPA1), which was observed to be increased in COPD43, was 
added to the network. Its effect on macrophages of increasing inter-
leukin-1 receptor-associated kinase 3 (IRAK3) and interleukin 1, 
beta (IL1B) were also added to the network during the open phase. 
Granularity enhancements around IFNG and nucleotide-binding 
oligomerization domain containing 2 (NOD2), both components of 
inflammatory signaling, were also added to augment the network 
models with causal relationships proximal to COPD.
During the Phase 3 jamboree discussions, several network enhance-
ments were made in macrophage chemotaxis and differentiation 
(Figure 6B). Within the chemotaxis process, the nodes chemokine 
(C-C motif) ligand 2 (CCL2) binding to chemokine (C-C motif) 
receptor 2 (CCR2) and leading to macrophage chemotaxis were 
added. The CD69 molecule (CD69) associated with macro-
phage activation by cigarette smoke was also added. In addition, 
the effects of activated macrophages on other immune cells were 
expanded within the network model, including chemokine (C-X-C 
motif) ligand 1 (CXCL1) and chemokine (C-X-C motif) ligand 2 
(CXCL2) leading to neutrophil chemotaxis, and chemokine (C-X-C 
motif) ligand 9 (CXCL9) and chemokine (C-X-C motif) ligand 10 
(CXCL10) binding to CXCR3 and leading to T cell recruitment. In 
total, 30 new nodes and 48 new edges were added to the Macro-
phage Signaling network during Phase 3, thereby providing a more 
comprehensive network of macrophage activation and its effect on 
other immune cells active in COPD.
Neutrophil signaling
As part of the pulmonary inflammatory process network building6, 
two networks (Neutrophil Response and Neutrophil Chemotaxis) 
were built to describe neutrophil biology in the non-disease lung 
context. During the preparation phase to NVC, these two networks 
were merged to constitute the Neutrophil Signaling network.
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Figure 6. Enhancement of the macrophage networks during COPD network construction. A) During the literature-based COPD 
enhancement process in Phase 1, efferocytosis mechanisms were added to the macrophage networks to take into account its dysregulation 
effect in COPD. B) During the jamboree discussions in Phase 3, chemotaxis and differentiation mechanisms were identified and subsequently 
added to the latest version of the Macrophage Signaling network. Triangle denotes activity, diamond denotes biological process, and square 
denotes protein abundance nodes. Solid edges denote causal relationships, dotted edges denote non-causal relationships such as a protein 
connected to its own activity.
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Phase 1: COPD augmentation of neutrophil networks
During Phase 1, the Neutrophil Signaling network was enhanced 
primarily with components related to lipid-response pathways. In 
response to lung damage, leukocytes and tissue-resident cells were 
reported to interact to generate lipid mediators that enhance the 
airway immune response and engage defense mechanisms44. Neu-
trophils, endothelial cells, and macrophages generate prostaglandins 
and leukotrienes from arachidonic acid during the initial inflam-
matory response, which amplifies the inflammation signals in the 
local area and potentiates the process of tissue destruction45. Sub-
sequently, the prostaglandins PGE2 and PGD2 are generated in a 
cyclooxygenase-dependent way to promote synthesis of lipid medi-
ators with anti-inflammatory activity, such as the lipoxins. Lipoxins 
inhibit neutrophil recruitment to inflamed sites and suppress their 
pro-inflammatory actions, but promote recruitment of macrophage 
precursors46. Lipoxin A4 stimulates macrophages to phagocytose 
apoptotic neutrophils, and resolvins and protectins, which represent 
another class of lipid mediators, activate anti-inflammatory path-
ways and stimulate clearance of inflammatory infiltrates by macro-
phage phagocytosis47–49. In total, 9 nodes and 20 edges were added 
to the network model including lipid mediators such as lipoxin A4, 
resolvin E1, and neuroprotectin D1 (Figure 7A).
Phases 2 and 3: Neutrophil network crowd improvements
The Neutrophil Signaling network was the network most edited 
by the crowd during the open phase, with the addition of 116 new 
nodes, 160 new edges, 181 new pieces of evidence, and 241 votes 
cast. The new edges described neutrophil chemotaxis including new 
nodes like platelet factor 4 (PF4) and protease-activated receptor 
2 (F2RL1). Chemokines such as chemokine (C-X-C motif) ligand 
8 (CXCL8) and chemokine (C-X-C motif) ligand 12 (CXCL12), 
and members of the serine/threonine kinase (AKT) family that have 
also been shown to induce neutrophil chemotaxis were added to the 
network (Figure 7B)50.
Figure 7. Enhancement of the neutrophil network during COPD network construction. A) During the literature-based COPD enhancement 
process in Phase 1, lipids and their effects on neutrophil chemotaxis were added to the new Neutrophil Signaling network. B) During Phases 
2 and 3, neutrophil adhesion and chemotaxis mechanisms were added to the new Neutrophil Signaling network. Triangle denotes activity, 
diamond denotes biological process, circle denotes abundance, and square denotes protein abundance nodes. Solid edges denote causal 
relationships, dotted edges denote non-causal relationships such as a protein connected to its own activity.
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Following the jamboree discussions, additional signaling that 
described cytoskeletal and adhesion mechanisms necessary for 
neutrophil chemotaxis, and additional neutrophil activation mecha-
nisms, were incorporated in the new Neutrophil Signaling network 
(Figure 7B). The role of the CDC42-WASp complex in regulating 
neutrophil chemotaxis at the cytoskeletal level was incorporated51, 
as well as other mechanisms of neutrophil chemotaxis includ-
ing the role of the complement component 5 (C5) in regulating 
integrin, alpha M (ITGAM)52, and the role of CCL3/CCR5 in 
stimulating neutrophil migration53. In all, 69 nodes and 129 edges 
were added. The new mechanisms that were incorporated into the 
Neutrophil Signaling network added significant granularity to the 
neutrophil chemotaxis process, which is a key driver of the inflam-
matory cascade that promotes the development of COPD.
Discussion
Here we report the construction of a COPD-enhanced network 
model set using a novel methodology that combined traditional 
manual literature curation and data-driven approaches with a global 
crowdsourcing endeavor to generate the most comprehensive repre-
sentation of biological phenomenon proximal to the onset of COPD 
that is available to date. The three phases of network construction 
each contributed in different ways to building a more compre-
hensive network. The Phase 1 literature and data-driven enhance-
ment of the already existing non-diseased networks resulted in the 
addition of COPD biomarkers and disease drivers known to be 
associated with COPD, while the Phase 2 crowdsourcing largely 
focused on contributions to cell-specific networks, and the Phase 3 
jamboree discussions uncovered missing signaling processes rel-
evant to COPD.
COPD biomarkers and processes added to non-diseased 
networks
During Phase 1, the non-diseased networks were expanded within 
the COPD context by the addition of biomarkers, disease drivers, 
and processes that were reported to increase in COPD, as well as 
mechanisms predicted in COPD data sets. Most of the edges added 
to the networks were lung relevant but not specifically investigated 
in a COPD background. Because of the limited number of mecha-
nistic studies in COPD models that have been published, network 
construction was focused on adding COPD-known processes and 
biomarkers in tissue and experimental contexts relevant for COPD 
(lung, smoking) to the existing non-disease networks.
Modeling the process of efferocytosis is an example of the addition 
of COPD processes to the non-disease networks. The efferocytosis 
process of phagocytic uptake of apoptotic cells by macrophages is 
frequently disrupted in COPD tissue, and this disruption is thought to 
potentiate the chronic state of inflammation in the diseased lung40–42. 
A new network model detailing components related to efferocy-
tosis was constructed from information available in the published 
literature with the majority of edges coming from general macro-
phage experiments. Th2 activation cascades and macrophage sign-
aling events were also implicated generally in the context of COPD, 
and therefore the non-diseased network models were enhanced by 
the addition of these pathways from lung-relevant studies. Net-
work models detailing other processes not widely implicated in 
COPD, such as DNA damage and Notch signaling, which are more 
generalized conserved biological phenomenon, received very few, 
if any, enhancements during the COPD literature curation phase.
In addition to adding COPD processes during Phase 1, we also added 
COPD biomarkers and mechanisms predicted by RCR to be active in 
COPD data sets. Biomarkers associated with COPD included chem-
okines, cytokines, matrix metalloproteinases (MMPs), and other 
matrix degradation products. Examples of cellular mechanisms 
uncovered by the data-driven approach included the cytokines IL19 
and IL3, as well as the serine protease inhibitor SERPINA1. IL3 is a 
growth-stimulating cytokine for many inflammatory cells, including 
macrophages, and IL19 is produced by monocytes and activates the 
inflammatory STAT3 pathway in several cell types. SERPINA1 is a 
potent elastase inhibitor, the presence of which plays a critical role 
in controlling the protease cascade leading to tissue destruction and 
emphysema. Overall, the RCR approach yielded a diverse range of 
biological features that were incorporated among a large percentage 
of the network models, thereby broadening the scope of many net-
works to include components with potential connections to disease 
that have not been investigated previously in the COPD context.
Crowdsourcing efforts focused on cell-specific networks
During the NVC, scientists from around the world browsed the 
publically available networks on a website, voted on and submitted 
new evidence, and created new nodes and edges. As may have been 
expected, several of the more well-studied processes in the literature 
(e.g. NF-kB pathways leading to inflammatory signaling) attracted 
a great deal of voting activity within the networks and primarily 
corroborated known biology. However, participants were incentiv-
ized to create new evidence to support existing edges based on the 
large number of points received by them for this activity. It was this 
aspect of the challenge that truly demonstrated the power of crowd-
sourcing because, in many instances, the community of users located 
lung-relevant and/or more recent publications to better support the 
existing network architecture and improve the overall relevance of 
the network models to COPD. With nearly 900 new pieces of evi-
dence (from 479 unique PMIDs) added by the challenge crowd, a 
significant overall enhancement of the networks was achieved in a 
relatively short time (5 months), which demonstrated the remark-
able utility of harnessing knowledge from the global scientific com-
munity for a specific application. Specifically, 30% (266/885) of all 
the new pieces of evidence and 46% (208/451) of all the new edges 
that were contributed fell within three network models, namely the 
Neutrophil Signaling, Macrophage Signaling, and Th1-Th2 Signal-
ing networks. These networks were edited more than other networks 
because of their clear boundaries, which allowed scientists to narrow 
their search to a particular cell type. Networks such as Clock, Wnt, 
mTor, and Regulation of CDKN2A expression were edited minimally 
and received more ‘Down’ votes than the cell-specific networks, 
possibly because of the more ambiguous boundaries of which cell 
types could be included. This observation emphasizes the need 
for clear boundaries in a crowdsourcing effort. In the case of gen-
eral networks such as Cell Cycle, Response to DNA Damage, and 
Oxidative Stress, many experiments concerning these processes 
have been performed in cell types that were excluded in our bound-
aries (i.e. tumorigenic cell lines). Perhaps boundary conditions 
could be loosened for networks such as these if it is assumed that 
signaling is conserved across different cell types.
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Jamboree discussions identified missing processes 
relevant to COPD
The final phase of network improvements emphasized the discussion 
and consolidation of all submissions from the challenge crowd to 
synthesize more holistic changes within the set of network models. 
During the challenge, participants worked individually on the web-
site adding individual edges, but did not have the ability to make 
major changes to the structure of the network models. The in-person 
jamboree discussions were therefore an opportunity to implement 
broader changes to better represent the biological processes as they 
related to COPD. These discussions were led by experts in the sub-
ject matter of the processes that the networks represented. During 
these sessions, missing pieces of biology and the interactions of 
different cell types in COPD were identified. In this manner, the 
jamboree was very conducive to broader network structural changes 
that made the set of network models more informative and repre-
sentative of processes implicated in COPD and, therefore, more 
useful to a broader group of scientists.
Unique features of the collaborative networks
In recent years, crowdsourcing has emerged as a powerful tool to 
address topics related to “big data” in the domain of the life sci-
ences, particularly in topics related to systems biology. For example, 
the series of DREAM challenges empowered the global scientific 
community to build application-specific, clinically relevant predic-
tive biological networks using vast quantities of genomic data54. 
Similarly, the recent sbv IMPROVER challenges allowed research-
ers to participate in collaborative competitions to validate systems 
biology research, for example, by testing and validating computa-
tional approaches that are used to classify clinical samples based 
on transcriptional data55–57. In the current approach, we describe a 
unique paradigm for biological network construction that combines 
a predictive computational methodology with a large-scale crowd 
sourcing approach to generate very comprehensive network models 
describing COPD pathogenesis.
Compared with other published COPD networks, the networks 
described here are more comprehensive in scope, are focused on 
molecular pathways that can drive disease rather than on descrip-
tions of more general clinical or physiological measures, and have 
been improved using crowdsourcing21–23. The Synergy-COPD 
European project is similar in its goal of creating a model of COPD 
for better understanding of the disease by combining information 
from many different sources. However, Synergy-COPD comprises 
seven physiological-focused mathematical networks rather than the 
50 molecular networks described here, and does not currently have 
an intuitive web interface that allows users to freely navigate the 
resulting networks23.
Compared with other more general pathway approaches such as 
KEGG1, the networks we describe contain edges that have one or 
more detailed evidences supported by a specific literature reference 
and contain tissue and species-level metadata. In our approach each 
of these pieces of evidence under an edge can be validated with 
the potential for a larger crowd with wide expertise, compared to 
a non-crowdsourced approach where the small group constructing 
the networks may not be able to sufficiently cover all the expertise 
necessary to verify every pathway within these networks. The BEL 
language syntax allows many participants to contribute by stand-
ardizing the biological representation and requiring that each node 
be associated with a namespace, which standardizes the representa-
tion of gene names and biological processes. The comparison of our 
network models with other resources has been described in other 
articles58,59 and in a book chapter60.
The web-based platform captures network provenance, allow-
ing for a transparent record of what has been validated with a full 
revision history58. The uncertainty for specific edges based on 
voting patterns can be demonstrated with the full voting history 
being captured in the network versions. By incorporating a con-
tinuous “feed” of real time enhancements submitted on the web-
site, users are able to view the most up-to-date networks at any 
time; network models created using other platforms not available 
for crowdsourced editing remain static representations of biology 
and frequently do not include the most recent findings from the 
scientific literature. Currently networks with the most recent crowd 
edits can be viewed, but not downloaded. Networks with changes 
from the most recent Jamboree meeting are made available for 
download.
Another novel component of these networks is the incorporation of 
RCR predictions to enhance the overall biological representation 
within the network models. RCR analysis was performed on human 
COPD gene expression data sets in the public domain in order 
to predict potential mechanisms implicated in COPD onset and 
include as nodes in the networks. This unbiased approach resulted 
in the addition of many new nodes among the networks predicted to 
be active based on COPD gene expression footprints that may have 
less well-established or direct connections to disease etiology. As 
such, this important aspect of network construction potentially cap-
tures those biological components that may have “emerging” roles 
in disease progression. The iterative nature of the network enhance-
ment process facilitated by the Bionet platform allows for new biol-
ogy and supporting evidence to be incorporated into the networks 
as new findings emerge in the literature and therefore generate the 
most comprehensive, up-to-date COPD model sets available to the 
scientific community.
The utility of the resulting networks and to further analyze the 
crowdsourcing process itself can be assessed by evaluating the 
impact of the changes on the analyses we have published previ-
ously60–67. Moreover, an extensive analysis leveraging multiple rel-
evant datasets will be conducted and the results will be published.
The enhanced crowd-verified models are publicly available on the 
sbv IMPROVER website (https://bionet.sbvimprover.com/) and 
remain open to receive further enhancements from the online com-
munity. Because the first iteration of the NVC proved the effective-
ness of this approach and because the networks can continue to be 
reviewed by the crowd, a second iteration of the NVC (NVC2) has 
been started so that additional modifications and recently published 
literature can be incorporated. This will help to continually refine 
the network models and strengthen the relevance to the processes 
that underlie the development of COPD. The crowd verification 
approach continues to be refined, so, in addition to disease process- 
centered networks, other networks including chemical-centered 
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networks can be built using a similar approach. These networks can 
aid in the development of more efficient interventions and enhance 
toxicological assessment of environmental exposures that may also 
contribute to the development of COPD.
Conclusion
Here we describe a novel approach to biological network construc-
tion and have generated a suite of COPD-relevant network models 
that the larger scientific community is free to edit and explore. Net-
works are available for download from the sbv IMPROVER web-
site (https://bionet.sbvimprover.com/) upon registration and taking 
a certain number of actions as a participant (e.g., voting on an evi-
dence). Scientists from all backgrounds are encouraged to submit 
additional network enhancements as participants in the NVC268. By 
building the network model set in the BEL language format, we 
have generated a model framework suitable for biomarker discov-
ery and for the interpretation of transcriptomic signatures59–66. More 
generally, this large assembly of biological knowledge relevant 
to human lung will be of great use to both academic and industry 
users in promoting future research in this area of great therapeutic 
importance.
Methods
Phase 1: COPD enhancement using data sets and literature
Networks that described molecular mechanisms of five broad bio-
logical processes were constructed previously using a literature 
and data mining approach. These networks cover mechanisms 
of cell proliferation5, cell stress4, DNA damage, autophagy, cell 
death and senescence3, pulmonary inflammation6, and tissue repair 
and angiogenesis7 in the non-diseased pulmonary context. To cre-
ate COPD-relevant networks, these non-diseased networks were 
enhanced by incorporating COPD mechanisms sourced using a lit-
erature and data set approach (Figure 1) in an iterative approach, as 
described in detail for the non-diseased network model construc-
tion, by a team of subject matter experts in computational biology, 
molecular biology, inhalation toxicology, and COPD.
Boundary conditions
Because the goal of the research was to understand COPD onset, 
the focus of these networks was on early stage COPD mechanisms 
(Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
stages I and II). When supporting literature from early COPD stud-
ies was not available, stage-independent COPD studies were used. 
When COPD studies were not found, the inclusion criteria were 
expanded to studies from non-diseased context, and mechanisms 
active in processes implicated in COPD were incorporated into the 
disease models. Literature describing the processes active in acute 
exacerbation in COPD patients was excluded from the supporting 
edges of the network models. In order to focus on the molecular 
mechanisms most specific to early stage COPD, we also excluded 
context from diseases with different pathogenesis and differential 
diagnosis: lung cancer and non-cancerous lung diseases, such as 
cystic fibrosis, acute respiratory distress syndrome, idiopathic 
pulmonary fibrosis, septic pneumonitis, obliterative bronchiolitis, 
pneumoconiosis, bronchiectasis, viral and bacterial infections, and, 
allergic responses/asthma, bronchitis. Animal inhalation studies 
with solid particles (e.g. titanium dioxide, quartz, asbestos, carbon 
black, and diesel exhaust) were also excluded due to their specific 
mode of action. Ideally, all nodes and edges of the network model 
would be supported by published data from experiments conducted 
in the tissues and cell types found in the lung under the conditions 
of early COPD, e.g., airway and alveolar epithelial cells, lung 
fibroblasts, resident and recruited immune cells, and microvascular 
cells. These were prioritized but the respective cell types were also 
considered from other tissue origin if such lung specific context 
was not reported in the literature. For in vitro-specific exclusion 
criteria, tumor-derived cell lines, immortalized cell lines, neuronal 
cells, and cell types that are not found in the respiratory/vascular 
system were excluded. In some cases, we made exceptions and 
included non-lung cell types for canonical mechanisms for which 
there was additional evidence from the literature that the relation-
ship was not tissue-specific but could also take place in the lung. 
Human-specific connections were prioritized, but where human data 
were not available, knowledge has been augmented with ortholo-
gous causal assertions derived from rat and mouse sources included 
after homologization in the Selventa knowledgebase where human 
data were not available5.
The 90 previously published non-diseased network models used for 
the initial substrate included networks involved in cell prolifera-
tion5, cell stress4, DNA damage, apoptosis, senescence, autophagy, 
necroptosis (DACS)3, pulmonary inflammation (IPN)6, and tissue 
repair and angiogenesis (TRAG)7. The Endothelial Shear Stress 
network from the cell stress model was excluded because the focus 
of the COPD Network was to describe lung biology.
Literature enhancement
We conducted a broad survey of the literature to locate studies that 
had investigated the mechanistic biology of COPD pathogenesis 
and processes involved in COPD. Potential COPD biomarkers from 
sputum, bronchoalveolar lavage, and mouse and human blood sam-
ples, and mechanisms that regulate COPD processes were gathered 
from the literature and curated. Because only a small number of the 
studies had focused on early COPD, we expanded our searches to 
include stage-independent COPD studies, but excluded late-stage 
processes. Some processes known to be closely linked to COPD 
pathogenesis (e.g. B-cell activation and T-cell recruitment to lung 
tissue) have not been studied directly in the disease context; how-
ever, literature that detailed cell-type-specific canonical biology 
was sourced irrespective of the disease context.
Data enhancement
RCR was performed using Gene Expression Omnibus (GEO) 
COPD and emphysema data sets from lung, small airway, and alve-
olar macrophages of early COPD patients and healthy smokers (see 
Dataset)69–73. RCR has been used previously to predict upstream 
regulators from transcriptomic data8. Mechanisms that were pre-
dicted by RCR to be active and that were not already incorporated 
in the non-diseased networks were vetted on an individual basis to 
locate supporting literature for their potential involvement in COPD 
pathogenesis. Mechanisms that had not been studied directly in a 
COPD context were evaluated in an expanded tissue context to con-
sider tissue deemed disease-relevant (e.g. alveolar macrophages). 
Mechanisms that were deemed relevant were connected in the most 
appropriate network based on their probable roles in COPD or lung 
biology.
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Network agglomeration
To generate a more concise model set for presentation to the crowd 
during the NVC, we consolidated networks associated with related 
biological processes among the 90 COPD-enhanced networks. An 
example of this consolidation is the merging of three non-disease net-
works related to T-helper 1 cells (Th1 Differentiation, Th1 Response, 
and T-cell Recruitment/Activation) into a single new Th1 Signal-
ing network. Fifty-six of the original 90 networks were combined 
into a concise set of 16 network models; the remaining 34 networks 
remained as standalone network models (see Dataset), yielding 
a final set of 50 models that were posted on the NVC website for 
review by the scientific crowd. In addition to the network agglom-
eration, protein, gene expression, and secretion edges were agglom-
erated to reduce the number of edges required for verification.
Phase 2: NVC Open Phase
The crowd verification process of improving biological networks 
has been published previously20. Briefly, the full set of 50 COPD-
relevant network models was posted on the BioNet web portal68 
for a period of 20 weeks (the “Open Phase”), during which time a 
global community of participants were invited to submit biological 
improvements to the models. The improvements included submis-
sion of new evidence, additional literature publications to support 
existing network edges, and submission of new biological edges 
with supporting evidence for relationships that were not repre-
sented in a network. Users could also vote on evidence to indicate 
agreement or disagreement with its appropriateness within the net-
work structure; disagreements often indicated improper tissue or 
experimental context for the given network. Evidence that received 
at least four ‘Up’ votes was “locked” to indicate crowd approval 
and evidence that received at least four ‘Down’ votes was “locked” 
to indicate rejection by the crowd. Depending on the frequency and 
type of submitted improvements, participants received credit points 
and were assigned a dynamic ranking on the community Leader-
board. For more information about the NVC challenge, see the 
5-minute overview videos at https://sbvimprover.com/challenge-
3/videos or the 1-hour webinars at https://sbvimprover.com/chal-
lenge-3/tutorials.
Phase 3: Jamboree meeting
When the open phase was closed, the top-ranked participants were 
invited to a 3-day-long in-person jamboree to discuss improvements 
submitted by the community and to further refine the network mod-
els. Subject matter experts in lung, COPD, and network biology, 
as well as experts in other related biological processes, were also 
invited to guide the discussions and to provide expert feedback of 
missing or misrepresented signaling. Scientists involved in the con-
struction of the original non-disease networks and Phase 1-enhanced 
networks were present to provide feedback for the rationale behind 
the boundary conditions and the mechanics of network construc-
tion and BEL. During the jamboree, 15 networks were prioritized to 
discuss in small groups of 6–10 people focusing on one network at 
a time. At the end of each session, final decisions were made about 
follow-up actions for each network and these actions were carried 
out subsequently by the scientists who constructed the original net-
works because of their familiarity with the mechanics of network 
construction and BEL.
The changes to the 15 networks that were discussed during the 
jamboree are posted online68 in open-source XGMML (eXtensible 
Graph Markup and Modeling Language) format.
BEL: the language of the networks
The networks were built using the Biological Expression Lan-
guage (BEL), which is an open source language that can represent 
scientific findings in the life sciences in a computable form74. 
BEL was designed to represent scientific findings by capturing 
causal and correlative relationships in context, where context can 
include information about the biological and experimental system 
in which the relationships were observed and the supporting pub-
lication citations. The structure of a BEL node, which includes 
the biological entity, the namespace or database to standardize the 
nomenclature of the entity, and the function that describes the type 
of entity (protein, chemical, biological process, family, complex, 
etc), is shown in Figure 8. Table 1 and Table 2 show the definition 
of the prefixes for BEL namespaces and functions that appear in 
the networks.
Figure 8. Structure of a BEL node. A BEL term is the standard way a node is described. It includes an entity that is described using standard 
nomenclature in the Namespace and the Function fields of the entity.
BEL Func�on
p(HGNC:AKT1)
Namespace
En�ty 
Biological entity of interest, 
e.g. gene, protein, chemical, 
biological process
Describes the specic form of 
the entity, e.g.:
a: abundance
bp: biological process
kin: kinase activity
Represents a public database containing the 
Entity to enable a standard nomenclature, 
e.g.:
HGNC, MGI, EGID, CHEBI, GO
p: protein abundance
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Table 2. BEL namespaces.
Prefix Namespace
EGID Entrez Gene Identifiers
HGNC HGNC Approved Gene Symbols
MGI MGI Approved Gene Symbols
RGD RGD Approved Gene Symbols
SPAC Swiss-Prot Proteins (Accession Numbers)
SP Swiss-Prot (Entry Names)
HGU95AV2 Affymetrix GeneChip Human Genome U95Av2
HGU133AB Affymetrix GeneChip Human Genome U133AB
HGU133P2 Affymetrix GeneChip Human Genome U133Plus2
MGU74ABC Affymetrix GeneChip Mouse Genome U74ABC
MG430AB Affymetrix GeneChip Mouse Expression Set 430
MG4302 Affymetrix GeneChip Mouse Genome 430 2.0
MG430A2 Affymetrix GeneChip Mouse Genome 430A 2.0
RG230AB Affymetrix GeneChip Rat Expression Set 230AB
RG2302 Affymetrix GeneChip Rat Genome 230 2.0
CHEBIID Chemicals of Biological Interest (Identifiers)
CHEBI Chemicals of Biological Interest (Names)
LMSD* LIPID MAPS Structure Database (Names)
GOAC GO Biological Processes (Accession Numbers)
GO GO Biological Processes (Names)
MESHPP MeSH Phenomena and Processes (Names)
MESHD MeSH Diseases (Names)
MESHCL MeSH Cell Locations (Names)
GOCCACC GO Cellular Component (Accession Numbers)
GOCCTERM GO Cellular Component (Terms)
PFH Named Human Protein Families
NCH Named Human Complexes
PFM Named Mouse Protein Families
NCM Named Mouse Complexes
PFR Named Rat Protein Families
NCR Named Rat Complexes
SCHEM Selventa Legacy Chemical Names
SDIS Selventa Legacy Disease Names
*Unofficial BEL namespace to be formalized in BEL 2.0
Table 1. BEL functions.
Prefix Function
a abundance
bp biological process
cat catalytic activity
sec cell secretion
surf cell surface expression
chap chaperone activity
complex complex abundance
composite composite abundance
deg degradation
fus fusion
g gene abundance
gtp GTP bound activity
kin kinase activity
m microRNA abundance
act molecular activity
path pathology
pep peptidase activity
phos phosphatase activity
p protein abundance
pmod protein modification
rxn reaction
ribo ribosylation activity
r RNA abundance
sub substitution
tscript transcriptional activity
tloc translocation
tport transport activity
trunc truncation
Data availability
Up-to-date networks including all users’ activity can be browsed 
freely on the Bionet website (https://bionet.sbvimprover.com/). 
Permanent URLs to each network are listed in the associated Data 
Set (Original networks, NVC networks and their descriptions). Net-
works can be downloaded by logged in users who had a few actions 
on the site as XGMML file for offline use in the version that started 
a verification phase, i.e. after review and QC by experts. The 15 
networks discussed in the jamboree are available in a post-jamboree 
version. Moreover, different versions of the networks are available 
to browse and download in diverse formats from the CBN database 
available at causalbionet.com.
Data availability
Figshare: Original networks, NVC networks and COPD data 
sets used in: Enhancement of COPD biological networks using a 
web-based collaboration interface http://dx.doi.org/10.6084/m9. 
figshare.128458375 
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Obstructive Pulmonary Disorders, early-stage COPD; a list of chemical compounds...) , what search
engines were used (e.g. PubMed), what collection (MEDLINE, PubMed Central full-texts). Additionally
quantitative details would be welcome also: how many abstracts or full-text articles were collected first?
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 12 May 2015
, Philip Morris, SwitzerlandStephanie Boue
Networks were built in multiple phases, as briefly described in M&M and in figure 1. The “original”
networks were built in a non-disease context as described in detail in the respective publications [
]. Based on relevant reviews in the area and context of interest, research papers that report the1-5
causal mechanistic relationships relevant for a specific biological process were identified and the
causal relationships were extracted and added to the model. Mechanistic relationships were also
added from an existing Knowledgebase, a collection of causal relationships curated over more
than ten years from over 40,000 papers and over 500,000 statements. 
 No competing interests were disclosed.Competing Interests:
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doi:10.5256/f1000research.6402.r7526
 Gary Bader
The Donnelly Centre, University of Toronto, Toronto, ON, Canada
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High quality curation by trained database curators is needed in our community to convert the literature to
computable models, but it is difficult to imagine how manual curation will scale to handle the ever-growing
data generation rate in biology. Thus, the biological research community needs to figure out how to get
crowdsourcing working for everyone as a tool to improve access to computable data. This paper does a
very good job of describing how a set of COPD networks were constructed and enhanced (they grew in
size and level of detail) through an interesting three-phase process. However, it would be useful to better
describe the utility of the resulting networks and to further analyze the crowdsourcing process itself.
Addressing these points will give the work a broader impact.
 
Utility of networks:
It is not clear what advantages the use of causal networks brings compared to more established models
in the community, such as molecular interaction networks used by many algorithms (e.g. gene function
prediction, module detection, interpretation of molecular profile data, network biomarkers) or detailed
biochemical pathway models (used by most textbooks and pathway databases). While many results are
published in terms of causal networks (e.g. A activates B), one important issue with networks constructed
by collecting these relationships is that they may be difficult to integrate across resources since they are
context specific: A may activate B in the lung, but inhibit B in the heart and when these are integrated, a
conflict arises. Many computational analysis methods require integration of networks from multiple
sources to construct the largest available network and integrate this data with disease-specific molecular
profile data (e.g. gene expression data) to gain context (as it seems is done in the RCR approach). It
would be useful for the authors to further discuss the utility of context-specific causal networks for follow
on discovery.
 
I only noticed one sentence mentioning use: “By building the network model set in the BEL language
format, we have generated a model framework suitable for biomarker discovery and for the interpretation
of transcriptomic signatures found in human lung tissue.” However, this sentence is not clear and doesn’t
cite any prior literature. How does using the BEL format create models suitable for biomarker discovery?
Can’t molecular interaction or other types of networks also be used for biomarker discovery? What type of
biomarker discovery is referred to here? How are transcriptomic signatures interpreted and analyzed?
 
Crowdsourcing comments:
“Networks that were not enhanced with COPD-specific mechanisms from the literature or RCR included
the DNA Damage and Notch Signaling networks. Although both these networks relevant to the
development of COPD, they were not augmented beyond the original, non-diseased network scaffolds,
because no studies on the differences in signaling between non-diseased and diseased states were
available.” How do the authors know that no relevant studies were available? It seems that many papers
at least have discussed links between COPD and DNA damage or Notch signaling (e.g. PMID: 19106307
published in 2009 “Down-regulation of the notch pathway in human airway epithelium in association with
smoking and chronic obstructive pulmonary disease.”)
 
“In total, 12 new nodes and 28 new edges were added to the Th1-Th2 Signaling network model during the
jamboree discussions, thereby creating a comprehensive biological network of T-helper cell activity and
their interactions with other immune cells in the context of COPD.”  How is ‘comprehensive’ measured?
How do we know how much of the available literature was covered by the crowdsource process? That is,
what is the sensitivity of the crowdsourcing process?
 
How many contributors were involved in enhancing each network in phase 2? Where were they from e.g.
academia, industry? What incentivized them to contribute – for instance, were they COPD researchers?
For the sake of research into crowdsourcing in biology, it would be very useful to provide additional
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academia, industry? What incentivized them to contribute – for instance, were they COPD researchers?
For the sake of research into crowdsourcing in biology, it would be very useful to provide additional
analysis of the contributor community. We need to learn more about what works and what doesn’t in
crowdsourcing initiatives so future generations of these approaches can be improved.
 
The authors state “With nearly 900 new pieces of evidence added by the challenge crowd, a significant
overall enhancement of the networks was achieved in a relatively short time (5 months),” How many
papers (PMIDs) supported the 900 pieces of evidence?
 
Questions about use of BEL:
Figure 4. The shorthand BEL notation is not widely recognized as a visual format and difficult to read in
general. An easy to read visualization format would make the network figures much easier to understand.
Also, what do the different edge end symbols (e.g. arrow, dot, diamond) mean?
 
Part C of Figure 1 mentions “BEL to openBEL conversion”. What’s the difference between BEL and
openBEL?
 
Other comments:
A broader review of the literature of pathway databases and crowdsourcing efforts should be included in
the introduction.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
Author Response 12 May 2015
, Philip Morris, SwitzerlandStephanie Boue
High quality curation by trained database curators is needed in our community to convert the
literature to computable models, but it is difficult to imagine how manual curation will scale to
handle the ever-growing data generation rate in biology. Thus, the biological research community
needs to figure out how to get crowdsourcing working for everyone as a tool to improve access to
computable data. This paper does a very good job of describing how a set of COPD networks were
constructed and enhanced (they grew in size and level of detail) through an interesting three-phase
process. However, it would be useful to better describe the utility of the resulting networks and to
further analyze the crowdsourcing process itself. Addressing these points will give the work a
broader impact.
 
: We have previously published several papers introducing use cases whereAuthors’ response
the biological signal is interpreted in a meaningful manner using the causal network models  and
have added these references to support the statement in the text. The point of the reviewer is
absolutely relevant and we acknowledge that it will be of utmost importance to critically assess how
the usefulness of the networks changed through each phase of the network verification project. As
a first step, the previously published analyses can be repeated with the crowd-verified networks to
assess the impact of network verification on data interpretation. A thorough assessment of the
impact of crowd verification, requires however an extensive analysis leveraging multiple relevant
datasets and to be reported thoroughly would dissolve the intended content of this manuscript that
concentrates on the way networks were built and later on verified and refined through a
crowdsourcing approach. We will conduct such an analysis and include the reference as soon as it
will become available. We have now addressed these points in the discussion.
1-7
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will become available. We have now addressed these points in the discussion.
Utility of networks:
It is not clear what advantages the use of causal networks brings compared to more established
models in the community, such as molecular interaction networks used by many algorithms (e.g.
gene function prediction, module detection, interpretation of molecular profile data, network
biomarkers) or detailed biochemical pathway models (used by most textbooks and pathway
databases). While many results are published in terms of causal networks (e.g. A activates B), one
important issue with networks constructed by collecting these relationships is that they may be
difficult to integrate across resources since they are context specific: A may activate B in the lung,
but inhibit B in the heart and when these are integrated, a conflict arises. Many computational
analysis methods require integration of networks from multiple sources to construct the largest
available network and integrate this data with disease-specific molecular profile data (e.g. gene
expression data) to gain context (as it seems is done in the RCR approach). It would be useful for
the authors to further discuss the utility of context-specific causal networks for follow on discovery.
 
 The usage of causal networks allows all applications that other networkAuthors’ response:
models would have, and in addition eases the biological interpretation of the results in a
mechanistic, cause and effect fashion. The new, sophisticated algorithms that have been
developed to analyze molecular data using the causal network models fully exploit the specific
structure of two-layer cause-and-effect network models, providing evidence that causality adds
precision on top of interaction . However, as the reviewer points out, causality may differ across
conditions (space and time), and the usage of BEL is therefore particularly relevant, as it allows for
detailed context annotation of each piece of evidence linked to a causal edge. To fully make use of
this property, it is important that as much of the literature evidence are collected in a
knowledgebase, which will only really be doable thanks to new text mining methods assisting the
biologists with the creation of BEL evidences or via crowdsourcing efforts such as the one
described here. Because it is a very large undertaking, we have so far tried to restrict the
evidences to respiratory and cardiovascular context. It is not excluded, however, that as the crowd
and interest for the network grows, a more comprehensive annotation of the networks are
achieved, making them usable in a specific context. Furthermore, BEL is being used in both
academic and industry settings and BEL converters are being developed that can translate
information from other sources such as BioPAX and SBML to facilitate comprehensive aggregation
of networks.
I only noticed one sentence mentioning use: “By building the network model set in the BEL
language format, we have generated a model framework suitable for biomarker discovery and for
the interpretation of transcriptomic signatures found in human lung tissue.” However, this sentence
is not clear and doesn’t cite any prior literature. How does using the BEL format create models
suitable for biomarker discovery? Can’t molecular interaction or other types of networks also be
used for biomarker discovery? What type of biomarker discovery is referred to here? How are
transcriptomic signatures interpreted and analyzed?
 
We have previously published several papers introducing use cases whereAuthors’ response: 
the biological signal is interpreted in a meaningful manner using the causal network models  and
have added these references to support the statement in the text. Martin describes theet al. 
development of network signatures that identify mechanisms that may explain differential drug
treatment response between individuals, demonstrating that the causal two layered networks allow
analyses which go beyond what normal networks can provide, i.e. provide classification power
1,2,8
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analyses which go beyond what normal networks can provide, i.e. provide classification power
coupled with mechanistic detail .
Crowdsourcing comments:
“Networks that were not enhanced with COPD-specific mechanisms from the literature or RCR
included the DNA Damage and Notch Signaling networks. Although both these networks relevant
to the development of COPD, they were not augmented beyond the original, non-diseased network
scaffolds, because no studies on the differences in signaling between non-diseased and diseased
states were available.” How do the authors know that no relevant studies were available? It seems
that many papers at least have discussed links between COPD and DNA damage or Notch
signaling (e.g. PMID: 19106307 published in 2009 “Down-regulation of the notch pathway in
human airway epithelium in association with smoking and chronic obstructive pulmonary disease.”)
 
 We reformulated the sentence. Although there may be papers that report onAuthors’ response:
the correlation between COPD and these processes like the Notch paper you mention, we are
referring to mechanistic papers that will provide causal links within the model. For example, a
paper from a NOTCH1 knockout experiment in a COPD animal model that shows a particular
protein being decreased will allow us to add the causal link of NOTCH1 activity increasing that
protein in the Notch signaling COPD model. These are the types of causal mechanistic papers we
have searched for and have not found in the context of COPD.
“In total, 12 new nodes and 28 new edges were added to the Th1-Th2 Signaling network model
during the jamboree discussions, thereby creating a comprehensive biological network of T-helper
cell activity and their interactions with other immune cells in the context of COPD.”  How is
‘comprehensive’ measured? How do we know how much of the available literature was covered by
the crowdsource process? That is, what is the sensitivity of the crowdsourcing process?
 
 As to avoid any confusion, and because the sensitivity of crowdsourcing isAuthors’ response:
not easily measurable (as it would require to assess all possible literature), we reformulated to
“more comprehensive”.
How many contributors were involved in enhancing each network in phase 2? Where were they
from e.g. academia, industry? What incentivized them to contribute – for instance, were they
COPD researchers? For the sake of research into crowdsourcing in biology, it would be very useful
to provide additional analysis of the contributor community. We need to learn more about what
works and what doesn’t in crowdsourcing initiatives so future generations of these approaches can
be improved.
 
 A specific publication addresses the statistics related to participation .Authors’ response:
Clearly, the most difficult part of such a crowdsourcing project is to get the right incentives for
people to participate. We acknowledge that showing the usefulness of the networks and their
refinements should allow for a bigger buy-in from the scientific community, and likely more
participation.
 
The authors state “With nearly 900 new pieces of evidence added by the challenge crowd, a
significant overall enhancement of the networks was achieved in a relatively short time (5 months),”
How many papers (PMIDs) supported the 900 pieces of evidence?
 
 479 unique PMIDs supported the 886 new pieces of evidence. We haveAuthors’ response:
included this detail in the text.
8
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included this detail in the text.
 
Questions about use of BEL:
Figure 4. The shorthand BEL notation is not widely recognized as a visual format and difficult to
read in general. An easy to read visualization format would make the network figures much easier
to understand. Also, what do the different edge end symbols (e.g. arrow, dot, diamond) mean?
We have added a legend to the figure. Please note that the bionet websiteAuthors’ response: 
also has a legend for the network visualization part.
 
Part C of Figure 1 mentions “BEL to openBEL conversion”. What’s the difference between BEL and
openBEL?
 
 BEL was a proprietary language developed by Selventa. In the interest of theAuthors’ response:
growing community of researchers using BEL, an openBEL language derived from BEL has been
developed and released as open source . One of the main differenceshttp://www.openbel.org/
between the two is that in the openBEL, the namespace (i.e. databases in which the biological
entity is defined) is clearly stated, allowing for a better standardization of used ontologies and
databases. We have added this specification in the figure legend.
 
Other comments:
A broader review of the literature of pathway databases and crowdsourcing efforts should be
included in the introduction.
 
 We have discussed the comparison of our network models with otherAuthors’ response:
resources in other publications . We have added this statement with appropriate references in
the discussion for readers, who wish to find more background information about the network
models and see how they compared with other approaches to interpret data.
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This work uses a hybrid approach network modelling approach to incorporate predictive methodology
with empirical knowledge and crowd sourcing for models of COPD pathogenesis. It is a good idea,
thoroughly implemented and has produced a potentially useful set of pathways. The value of the resulting
pathways is not clear as they do not have community validation, only community design.
The manuscript is exhaustive in its descriptions and the process of developing the models is clear.
The work represents the first phase of understanding for knowledge driven development of
network models of COPD - the process of building the models is well described and the actual outcomes
of the interactions with community are informative. The question of the actual true value of the models in
terms of their accuracy, adoption and  accessibility is not yet convincingly addressed. That may be
expected as the purpose of this work appears to be a description of the first part of the process of
developing knowledge based models for a disease. The models as presented appear unvalidated
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developing knowledge based models for a disease. The models as presented appear unvalidated
and without a description of the framework for assessing the value and actioning of the networks, it is not
clear how their uptake by the community will be assured.
This is a unique effort but the manuscript should make more reference to
existing pathway based community annotation efforts e.g.: wikipathways and/or open science initiatives
such as those promoted by community interaction leaders such as Andrew Su. It should show how the
value of this approach differs to existing efforts.
In terms of access to expertise, it is not clear how an uninvited scientist would contribute to an existing
pathway model - except through the open but time-limited crowdsourcing venue.
Straightforward validation of the models network is not tested in terms of their consistency or
cross-valdiation within COPD high dimensional assays - where it should be possible to see evidence of
enrichment for co-expression etc.
Contextual nature of networks is mentioned and attempts are made to address contextual pathway
structures, but the context is not tested.
As a suggestion the authors should consider community validation
Pathway accessibility and distribution is described but it is not clear as to how these models are available
in any format except web browsing. For the models to be tested by the community, value would come
from making them openly available as downloadable instances in several of the most popular formats.
Feedback on their accuracy could then be encouraged.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 I was an invitee to one of the Improver conferences to present a talk but did notCompeting Interests:
contribute to the manuscript or models. I know S. Boue as a previous collaborator and colleague on a
publication "ASTD: The Alternative Splicing and Transcript Diversity database.,” vol. 93, no. 3, pp.
213–220, Mar. 2009."
Author Response 12 May 2015
, Philip Morris, SwitzerlandStephanie Boue
This work uses a hybrid approach network modelling approach to incorporate predictive
methodology with empirical knowledge and crowd sourcing for models of COPD pathogenesis. It is
a good idea, thoroughly implemented and has produced a potentially useful set of pathways. The
value of the resulting pathways is not clear as they do not have community validation, only
community design. The manuscript is exhaustive in its descriptions and the process of developing
the models is clear.
The work represents the first phase of understanding for knowledge driven development of
network models of COPD - the process of building the models is well described and the actual
outcomes of the interactions with community are informative. The question of the actual true value
of the models in terms of their accuracy, adoption and  accessibility is not yet
convincingly addressed. That may be expected as the purpose of this work appears to be
a description of the first part of the process of developing knowledge based models for a disease.
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a description of the first part of the process of developing knowledge based models for a disease.
The models as presented appear unvalidated and without a description of the framework for
assessing the value and actioning of the networks, it is not clear how their uptake by the
community will be assured.
 The point of the reviewer is absolutely relevant and we acknowledge that itAuthors’ response:
will be of utmost importance to critically assess how the usefulness of the networks changed
through each phase of the project. Whenever possible, orthogonal data sets were used to validate
the network model during the building process. In the paper Systematic verification of upstream
regulators of a computable cellular proliferation network model on non-diseased lung cells using a
, we have done just that by using a specifically designed, independent lung celldedicated dataset
proliferation dataset to verify the correctness of the cell cycle network model . The validation of all
available networks requires an extensive analysis leveraging multiple relevant datasets and to be
reported thoroughly would dissolve the intended content of this manuscript that concentrates on
the way networks were built and later on verified and refined through a crowdsourcing approach.
We will conduct such an analysis and make sure to reference it here as soon as it will be available.
This is a unique effort but the manuscript should make more reference to
existing pathway based community annotation efforts e.g.: wikipathways and/or open science
initiatives such as those promoted by community interaction leaders such as Andrew Su. It should
show how the value of this approach differs to existing efforts.
We have discussed the comparison of our network models with otherAuthors’ response: 
resources in other articles   and in a book chapter . We have added this statement in the
discussion for readers who wish to find more background information about the network models
and see how they compared with other approaches to interpret data.
In terms of access to expertise, it is not clear how an uninvited scientist would contribute to an
existing pathway model - except through the open but time-limited crowdsourcing venue.
Straightforward validation of the models network is not tested in terms of their consistency or
cross-valdiation within COPD high dimensional assays - where it should be possible to see
evidence of enrichment for co-expression etc.
Contextual nature of networks is mentioned and attempts are made to address contextual pathway
structures, but the context is not tested.
As a suggestion the authors should consider community validation
Pathway accessibility and distribution is described but it is not clear as to how these models are
available in any format except web browsing. For the models to be tested by the community, value
would come from making them openly available as downloadable instances in several of the most
popular formats. Feedback on their accuracy could then be encouraged.
 
: The networks can be browsed on the  website,Authors’ response bionet.sbvimprover.com
including latest votes and modification. More stable versions are stored in the causalbionet.com 
database .
 
1
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